HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Couch, L. A. Search for Related Content PubMed PubMed Citation Articles by Couch, L. A.

Treatment With Tobramycin Solution for Inhalation in Bronchiectasis Patients With Pseudomonas aeruginosa^*

^* From the Department of Pulmonary and Critical Care Medicine, The University of Texas Health Center at Tyler, Tyler, TX.

Correspondence to: Leslie A. Couch, MD, FCCP, The University of Texas Health Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708-3154; e-mail: Leslie.couch{at}uthct.edu

A randomized, placebo-controlled, multicenter trial evaluated the safety and efficacy of 300 mg aerosolized tobramycin solution for inhalation (TSI) administered twice daily for 4 weeks in 74 bronchiectasis patients colonized with Pseudomonas aeruginosa (PA). Patients were evenly divided between TSI therapy and placebo. After 2 weeks of treatment, patients treated with TSI had a mean reduction in sputum PA density of 4.8 log_10. This reduction was maintained for the duration of treatment. The placebo group showed no change in PA density during the study. Two weeks after the end of therapy, PA had been eradicated in 13 TSI-treated patients. PA was not eradicated in any placebo patients. Among those colonized with Staphylococcus aureus at baseline, 6 of 9 patients in the TSI group and 2 of 9 patients in the placebo group were culture negative for this organism 2 weeks posttreatment. Sixty-two percent of TSI-treated patients were judged by a physician as having an improved general health status, compared with 38% of placebo-treated patients. Dyspnea, wheezing, and chest tightness were reported more frequently in the TSI-treated patient group than in the placebo-treated patient group.

Key Words: bronchiectasis • Pseudomonas aeruginosa • tobramycin solution for inhalation

This article has been cited by other articles:

				D. Bilton, N. Henig, B. Morrissey, and M. Gotfried Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis. Chest, November 1, 2006; 130(5): 1503 - 1510. [Abstract] [Full Text] [PDF]